文献速递主动脉外科

分支型胸主动脉腔内修复术急诊治疗主动脉弓病变的初步经验

Emergency Use of Branched Thoracic Endovascular Repair in the Treatment of Aortic Arch Pathologies.
PubMed 文献 · Ann Thorac Surg · 2018-10-30

本研究回顾性分析了11例接受急诊分支型胸主动脉腔内修复术(b-TEVAR)的主动脉弓病变患者,技术成功率100%,30天死亡率为9%,早期再干预率为45%。随访中位6个月,2例存在持续假腔灌注,但所有主动脉上分支保持通畅。结果表明急诊b-TEVAR可行且安全,但早期再干预率不容忽视。

要点

  • 急诊b-TEVAR技术成功率100%,30天死亡率9%。
  • 早期再干预率45%,围术期并发症包括卒中、脓毒症等。
  • 中位随访6个月,所有主动脉上分支通畅,2例假腔持续灌注。

核心结论

  • 急诊b-TEVAR治疗主动脉弓病变可行且安全,但早期再干预率较高。

研究设计与样本

  • 回顾性研究,纳入2012年12月至2017年12月单中心11例急诊b-TEVAR患者(5例男性,年龄67±14岁)。

主要发现

  • 技术成功率为100%(11/11)。
  • 30天死亡率为9%(1/11)。
  • 围术期并发症包括重大卒中1例(9%)、脓毒症1例(9%)、呼吸衰竭2例(18%)、急性肾损伤1例(9%)和腹膜后血肿1例(9%)。
  • 早期再干预5例(45%)。
  • 中位随访6个月(范围1-28个月),2例存在持续假腔灌注,所有主动脉上分支保持通畅。

临床怎么用

  • 在急诊情况下,b-TEVAR可作为主动脉弓病变的治疗选择,但需警惕早期再干预风险。
  • 支架移植物可从其他相似解剖患者借用,实现急诊使用。

局限性

  • 样本量小(11例),为单中心回顾性研究。
  • 随访时间较短(中位6个月)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Branched thoracic endovascular aortic repair (b-TEVAR) has revolutionized the treatment of aortic arch pathologies. However, b-TEVAR requires custom design and time for manufacturing, which limits its use in emergency situation. METHODS: We retrospectively studied a series of 11 patients, who underwent emergency b-TEVAR in our institution. Stent grafts were either already available for the patient or from another patient with similar anatomy. Study endpoints were technical success, 30-day mortality, perioperative complications, early reinterventions, and subsequent image follow-up. RESULTS: Between December 2012 and December 2017, 11 patients (5 male; age 67 ± 14 years) were treated emergently with b-TEVAR for type A dissection (n = 2), peripheral malperfusion despite ascending repair in type A dissection (n = 1), contained ruptured ascending aortic pseudoaneurysm (n = 2), symptomatic arch aneurysm (n = 4), and ruptured subclavian aneurysm (n = 2). Three patients received their personal custom-made endografts but were hospitalized and treated urgently because of new symptom onset; the remaining 8 patients were treated with endografts from other patients. Technical success was 100%. Thirty-day mortality was 9% (1 of 11). Perioperative complications included one major stroke (9%), one sepsis (9%), two respiratory failures (18%), one acute renal injury (9%), and one retroperitoneal hematoma (9%). There were five (45%) early reinterventions. With median 6 months (range, 1 to 28) of follow-up, 2 patients had persistent false lumen perfusion, whereas all supraaortic branches remained patent. CONCLUSIONS: Our experience provided an early insight to the feasibility and safety of b-TEVAR in an emergency situation, although the early reintervention rate was not negligible. The endograft was versatile, with potential off-the-shelf use in future.

来源:Ann Thorac Surg,查看原文。版权归原作者所有。

引用

  1. Law Y, Kölbel T, Detter C, et al. Emergency Use of Branched Thoracic Endovascular Repair in the Treatment of Aortic Arch Pathologies. Ann Thorac Surg. 2018. PMID: 30389447. doi:10.1016/j.athoracsur.2018.09.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。